Last reviewed · How we verify

Coumarin/troxerutin

Takeda · FDA-approved active Small molecule

Coumarin/troxerutin is a bioflavonoid combination that strengthens blood vessel walls and reduces capillary fragility through antioxidant and venoprotective effects.

Coumarin/troxerutin is a bioflavonoid combination that strengthens blood vessel walls and reduces capillary fragility through antioxidant and venoprotective effects. Used for Chronic venous insufficiency, Lymphedema, Hemorrhoids.

At a glance

Generic nameCoumarin/troxerutin
Also known asVenalot®
SponsorTakeda
Drug classVenoprotective agent / Bioflavonoid combination
ModalitySmall molecule
Therapeutic areaCardiovascular / Vascular
PhaseFDA-approved

Mechanism of action

Troxerutin, a semisynthetic flavonoid derivative, works synergistically with coumarin to improve microcirculation and reduce vascular permeability. The combination enhances endothelial function and reduces inflammatory responses in blood vessels, thereby improving venous tone and reducing edema. These agents are used primarily for their venoprotective and lymphoprotective properties in chronic venous insufficiency.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results